Table 2.
Sleep duration, colon cancer recurrence and mortality.
| Average sleep duration (hours) | ||||||
|---|---|---|---|---|---|---|
| ≤ 5 | 6 | 7 | 8 | ≥9 | *Pnon-linear | |
| Disease-free survival | ||||||
| # Event/at risk | 24/129 | 36/231 | 61/411 | 44/291 | 28/113 | |
| Age- and caffeine intake-adjusted only, HR (95% CI) | 1.23 (0.77–1.98) | 1.03 (0.68–1.56) | Ref | 0.98 (0.67–1.45) | 1.70 (1.08–2.68) | 0.03 |
| Multivariable-adjusted, HR (95% CI)a | 1.33 (0.83–2.15) | 1.01 (0.67–1.53) | Ref | 0.96 (0.65–1.41) | 1.66 (1.05–2.63) | 0.02 |
| Multivariable-adjusted, HR (95% CI)b | 1.35 (0.83–2.20) | 1.07 (0.70–1.63) | Ref | 0.96 (0.65–1.43) | 1.62 (1.01–2.58) | 0.03 |
| Overall survival | ||||||
| # Event/at risk | 17/129 | 12/231 | 26/411 | 20/291 | 20/113 | |
| Age- and caffeine intake-adjusted only, HR (95% CI) | 2.13 (1.15–3.93) | 0.87 (0.44–1.73) | Ref | 1.03 (0.58–1.85) | 2.63 (1.45–4.77) | <0.001 |
| Multivariable-adjusted, HR (95% CI)a | 2.26 (1.22–4.20) | 0.83 (0.42–1.66) | Ref | 0.99 (0.55–1.79) | 2.45 (1.34–4.49) | <0.001 |
| Multivariable-adjusted, HR (95% CI)b | 2.14 (1.14–4.03) | 0.87 (0.44–1.74) | Ref | 0.97 (0.53–1.75) | 2.34 (1.26–4.33) | <0.001 |
*P value for non-linear trend was estimated by including a quadratic term for sleep duration variable.
aMultivariable-adjusted model adjusted for age, caffeine intake, sex, T-stage, N-stage, ECOG performance status and alcohol consumption.
bMultivariable-adjusted model adjusted for age, caffeine intake, sex, T-stage, N-stage, ECOG performance status, alcohol consumption, physical activity, BMI, smoking status, any neuropathy or grade 3+ toxicities during follow-up, and relative dose intensities of fluorouracil and oxaliplatin.